Is palpation of the nonresected pulmonary lobe(s) required for patients with non–small cell lung cancer? A prospective study  by Cerfolio, Robert James & Bryant, Ayesha S.
G
TS
Cerfolio and Bryant General Thoracic SurgeryIs palpation of the nonresected pulmonary lobe(s)
required for patients with non–small cell lung cancer?
A prospective study
Robert James Cerfolio, MD, FACS, FCCP,* and Ayesha S. Bryant, MSPH, MDy
Objective: Video-assisted lobectomy is an increasingly used technique to treat pa-
tients with non–small cell lung cancer but it does not usually afford lung palpation.
Methods: A prospective study was conducted on patients with tumors amenable to
video-assisted lobectomy (noncentral lesion and,5 cm) who underwent open lobec-
tomy via thoracotomy. All patients underwent 64-slice helical computed tomographic
scan with intravenous contrast at 5-mm intervals and had integrated 2-deoxy-2-18F-
fluoro-D-glucose positron emission tomography computed tomography 30 days or
less before thoracotomy. Unsuspected malignant pulmonary nodules that were
palpated and removed (from a different lobe than the one resected) and that were
not imaged preoperatively were defined as cancer that would have been missed by
video-assisted lobectomy.
Results: From January 2006 to February 2007, 166 patients had non–small cell lesions
that were resected via thoracotomy, despite being amenable to video-assisted surgery,
by one surgeon. Thirty-seven (22%) patients had pulmonary nodules that probably
would have been missed by video-assisted lobectomy; 14 (8.4%) of these nodules
were malignant. These were unsuspected M1 pulmonary lesions in 9 patients and un-
suspected different types of primary non–small cell lung cancers in 5 patients. All
missed lesions were less than 6 mm and in different lobes from the one resected.
Nine (64%) of these 14 patients’ primary known lesions were pathologic T1 lesions.
Nine patients received adjuvant chemotherapy because of these unsuspected M1
nodules.
Conclusions: Open lobectomy that affords palpation of the rest of the lung may dis-
cover nonimaged malignant pulmonary nodules in different lobes in 8% to 9% of pa-
tients with non–small cell lung cancer despite preoperative fine-cut chest computed
tomographic scan with contrast and integrated integrated 2-deoxy-2-18F-fluoro-D-
glucose positron emission tomography computed tomographic scanning. The clinical
impact of these findings is unknown.
L
ung cancer remains the most common cause of cancers deaths worldwide,
and 80% of lung cancers are non–small cell lung cancer (NSCLC). These
types of tumors are potentially curable if detected early and surgically re-
sected. Recently, many centers and surgeons have adopted video-assisted thoracic
surgery (VATS) techniques to perform pulmonary resection for bronchogenic ma-
lignancy mainly because it is touted as less invasive and leads to quicker recovery
in most patients.1,2 In addition, it has been purported to have similar oncologic
efficacy, and in a few series from several experienced VATS surgeons the long-
term survival is reported to be similar to that of open techniques. In 2005 we3 per-
formed a prospective study that showed the inaccuracies of clinical staging
compared with pathologic staging. Only about 50% of patients had their stage cor-
rectly predicted despite use of the most sophisticated preoperative imaging studies
available. Some patients had malignant nodules that were missed despite the use of
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TSAbbreviations and Acronyms
CT 5 computed tomography
FDG-PET/CT 5 2-deoxy-2-18F-fluoro-D-glucose positron
emission tomography computed
tomography
maxSUV 5 maximum standardized uptake value
NSCLC 5 non–small cell lung cancer
PET 5 Positron emission tomography
UAB 5 University of Alabama at Birmingham
VATS 5 video assisted thoracoscopic surgery
integrated 2-deoxy-2-18F-fluoro-D-glucose computed tomo-
graphic scans (FDG-PET/CT) and fine-cut, 64-multislice
chest computed tomography (CT) scan using intravenous
contrast. The finding of missed or nonimaged malignant pul-
monary nodules for patients who undergo thoracotomy for
metastasectomy is well chronicled and is estimated to be
11% to 48%, with most series reporting approximately
20%.4-10 Therefore, many surgeons believe that bimanual
lung palpation is best for patients who undergo metastasec-
tomy. Does this concept apply for those with NSCLC? The
objective of this study was to evaluate the incidence of non-
imaged pulmonary nodules discovered at the time of open
thoracotomy via bimanual lung palpation that were missed
by the preoperative chest CT scan and integrated FDG-
PET/CT in patients who had NSCLC that was potentially re-
movable by VATS.
Patients and Methods
This was a prospective cohort study over 13 months (January 2006
to February 2007). Entry criteria mandated patients have a chest CT
and an integrated FDG-PET/CT scan within 4 weeks of surgery,
pathologically confirmed NSCLC, and a VAT-able lesion as defined
below. Chest CT scan had to be at least 64 slices, with 5-mm cuts,
and patients had to receive intravenous contrast. Exclusion criteria
were any pathologic condition other than NSCLC, including meta-
static disease, preoperative radiation therapy, or patient age less than
19 years. Patients who underwent metastasectomy were eliminated
from this study because of their involvement in another prospective
study evaluating a similar question in patients with other types of
cancer besides NSCLC. The chest CT scans and the integrated
FDG-PET/CT scan that were performed at our institution were per-
formed as described previously.11,12 An estimated TNM stage of the
tumor was derived after the integrated FDG-PET/CT scan and after
the chest CT scan.13 The University of Alabama at Birmingham
(UAB) Institutional Review Board approved this study, and it sep-
arately approved the prospective database used to compile these
data. Patient consent was obtained for inclusion in our prospective
database only.
A pre-study statistical power analysis where a5 .05 and a power
of 80% in a 2-sided test was used to determine the sample size re-
quired for this series. Incidence was approximated at 8% for pur-
poses of sample size calculation. Summaries for continuous
variables are presented as medians. Frequencies with percentages
were generated for categorical variables. Categorical values were262 The Journal of Thoracic and Cardiovascular Surgery c Febcompared by analysis of variance, the c2 test, or the Fisher exact
tests. Continuous variables were compared by the Student t test
for normally distributed variables and the Wilcoxon test for nonnor-
mally distributed variables.
Definitions
A ‘‘VATable NSCLC lesion’’ was defined as any nodule or
mass less than 5 cm that did not invade nor extrinsically com-
press a lobar or more central bronchus. A bronchoscopic ex-
amination without evidence of cancer in the segmental or
lobar bronchus was also required for a lesion to be considered
VATable for this study. A ‘‘non-VATable’’ pulmonary lesion
was defined as any other nodule or mass in the lung. A non-
imaged pulmonary nodule, also labeled a nodule that ‘‘would
have been missed had a VATS lobectomy been performed,’’
was defined as a pulmonary nodule in a lobe other than the
one that contained the known described primary lesion and
it was not described on the chest CT or the integrated PET/
CT scan reports. Missed pulmonary nodules were then later
subdivided as malignant nonimaged pulmonary nodules or
benign nonimaged pulmonary nodules on the basis of the
pathologic examination.
Results
As shown in Figure 1, there were 1384 patients who under-
went surgery by one surgeon from January 2006 to February
2007. Six-hundred twenty-eight patients underwent pulmo-
nary resection and 166 had VAT-able NSCLC lesions (as
Figure 1. Study algorithm: There were 1384 operations performed
by one surgeon from January 2006 until February 2007, and 628
were pulmonary resections. Of those, 302 were eligible for this
study. NSCLC, Non–small cell lung cancer; VATS, video-assisted
thoracic surgery; CW, chest wall.ruary 2008
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TSTABLE 1. Characteristics of patients by group (group 1, no pulmonary nodules nonimaged; group 2, benign pulmonary
nodules missed; and group 3, malignant pulmonary nodule nonimaged)
No missed pulmonary nodules
(n 5 129)
Benign missed pulmonary nodule
(n 5 23)
Missed malignant pulmonary nodule
(n 5 14)
Median age 62 64 65
Gender (male) 83 (64%) 13 (57%) 9 (64%)
Operative procedures
Resected 122 (95%) 23 14
Not resected 7 (5%) 0 0
Histology of preoperatively
imaged lesion
Adenocarcinoma 59 (45%) 8 (35%) 4 (29%)
Squamous 55 (43%) 12 (52%) 7 (50%)
BAC 6 (5%) 2 (9%) 2 (14%)
Carcinoid 4 (3%) 1 (4%) 0 (0%)
Other 5 (4%) 0 (0%) 1 (7%)
MaxSUV of preoperatively
imaged pulmonary nodule,
median (range)
4.1 (,2.5–16.4) 4.3 (,2.5–12.2) 4.95 (,2.5–13.9)
Location of CT scan at UAB 106 (82%) 16 (70%) 11 (79%)
Outside 23 (18%) 7 (30%) 3 (21%)
BAC, Bronchoalveolar carcinoma; maxSUV, maximum standardized uptake value; CT, computed tomographic; UAB, University of Alabama at Birmingham.defined above) The most common causes for a lesion to be
considered non-VAT-able were tumor size greater than 5
cm and a history of previous radiation. Patient characteristics
are shown in Table 1. Univariate analysis showed a statisti-
cally significant difference only in the maximum standard-
ized uptake value (maxSUV) of the preoperatively imaged
pulmonary nodules. Patients who had CT scans performed
at outside institutions were not more likely to have missed,
nonimaged pulmonary nodules. The 14 patients with a missed
malignant pulmonary nodule (nodules discovered only via
bimanual lung palpation, not finger palpation) had a higher
median maxSUV (5.0) than did the 152 patients who did
not have a missed malignant nodule (4.1; P 5 .045.). The
data are stratified into three groups: those with no palpated
nonimaged pulmonary nodules, those with benign nonim-
aged pulmonary nodules, and those with malignant nonim-
aged pulmonary nodules. As shown, 37 (22%) patients had
a nodule that was nonimagined. Fourteen (8.4%) of these
missed nodules were malignant. Table 2 depicts the patho-
logic characteristics of these 14 patients who had nonimaged
malignant nodules. There were unsuspected M1 pulmonary
lesions (nodules of the same histologic type as that in the pri-
mary, preoperatively imaged tumor but in a different lobe) in 9
patients and unsuspected different types of NSCLC primary
tumors in the remaining 5 patients. All nonimaged lesions
were 6 mm or less and all were, by definition, in different lobes
from the one resected. Nine (64%) of the 14 patients with a pri-
mary larger lesion had pathologic T1 lesions, and 3 (21%) had
T2, and 2 had T4 (because they had 2 nodules of the same his-
tologic type in the same lobe). Thus these 2 latter patients hadThe Journal of Tho2 nonimaged malignant nodules, 1 in the lobe that was re-
sected and 1 in a different lobe. Table 3 shows the distribution
of the nonimaged nodules by the location of the known pri-
mary NSCLC. When we collapse this information, we find
that patients with lower lobe cancers had a higher incidence
of nonimaged pulmonary nodules (44% compared with
16%; P , .01) and a higher incidence of nonimaged malig-
nant pulmonary nodules (16% compared with 6%, P5 .04).
Finally, in addition to the patients with nonimaged pulmo-
nary nodules, there were other patients who had a pathologic
stage that differed from the predicted clinical PET/CT–sug-
gested stage (not including those with T-stage disagree-
ments). There were 12 patients who had unsuspected
metastatic NSCLC in one or more mediastinal lymph nodes
(N2 disease).
Discussion
Patient selection is an important component of successful
surgical outcomes for patients with NSCLC. This entails
not only the careful assessment of the patient’s cardiopulmo-
nary risks before the operation, but also their oncologic stage,
which determines the best treatment strategies during the op-
eration. For example, the discovery of metastatic disease in
a mediastinal (N2) lymph node before pulmonary resection
often changes the preoperative management. Similarly, the
discovery of pathologic N1, N2, or M1 disease after resection
often changes the postoperative therapy as well. Therefore,
meticulous intraoperative staging is a critical aspect of the op-
eration and removal of the suspected or known malignant
pulmonary nodule alone is insufficient.racic and Cardiovascular Surgery c Volume 135, Number 2 263
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TSTABLE 2. Clinical and pathologic characteristics of the 14 patients who had missed malignant nodules by preoperative
chest CT and FDG-PET/CT scan
Clinical stage
Pt No.
CT
stage
PET/CT
stage
MaxSUV
primary
Tumor location
and size (cm) Histology
Pathologic stage
and histology Impact on therapy
1 T1 T1 4.6 RLL, 2.3 Squamous cell T1 N0 M1 Referred for radiochemotherapy.
N0 N0 RML, 0.3
2 T2 T2 4.0 RUL, 2.0 Squamous cell T1 N0 M0 None
N0 N0 RLL, 0.5 Carcinoid T1 N0 M0
3 T1 T0 ,2.5 LUL, 2.5 Bronchoalveolar carcinoma T4 N0 M1 Referred for chemotherapy
N0 N0 LLL, 0.6
4 T2 T2 3.7 LLL, 3.5 Adenocarcinoma T1 N0 M0 Referred for chemotherapy
N0 N0 LUL, 0.6 Adenocarcinoma T1 N2 M0
5 T2 T2 9.1 LUL, 4.4 Adenocarcinoma T2 N0 M1 Referred for chemotherapy.
N0 N1 LLL, 0.5
6 T2 T2 7 RUL, 2.0 Squamous cell T2 N0 M1 Referred for radiochemotherapy
N0 N0 RLL, 0.6
7 T1 T1 5.3 LLL, 2.2 Adenocarcinoma T1 N0 M0 None
N0 N0 LUL, 0.6 Mixed T1 N0 M0
8 T2 T2 8.1 RLL, 2.3 Squamous cell T1 N0 M0 None
N0 N0 RML, 0.5 Carcinoid T1 N0 M0
9 T1 T1 3.7 RLL, 1.2 Adenocarcinoma T1 N0 M1 Referred for chemotherapy
N0 N0 RML, 0.3
10 T1 T1 8.0 LUL, 2.9 NSCLC T1 N0 M1 Referred for chemotherapy
N0 N0 LLL, 0.6
11 T1 T1 4.0 LUL, 2.1 Squamous cell T1 N2 M1 Referred for chemotherapy
N2 N2 LLL, 0.5
12 T2 T2 7.3 RUL, 4.9 Squamous cell T4 N0 M1 Referred for radiochemotherapy
N1 N0 RML, 0.6
13 T2 T2 13.9 LUL, 3.5 Squamous T1 N0 M0 None
N2 N0 LLL, 0.5 Adenocarcinoma T2 N0 M0
14 T2 T3 3.5 RLL, 4.9 Bronchoalveolar carcinoma T2 N2 M1 Referred for chemotherapy
N0 N0 RUL, 0.6
CT, Computed tomography; FDG-PET/CT, 2-dexoy-2-18F-fluoro-D-glucose positron emission tomography computed tomography; RUL, right upper lobe; RML,
right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe. Shaded boxes indicate an unsuspected nodule.In this prospective study, we found that that 22% (37/166)
of patients had a pulmonary nodule that was not imaged by
the helical, thin-slice, contrasted chest CT scan and discov-
ered only via bimanual lung palpation. None of these lesions
was palpated via finger palpation of the surface of the lung as
one is able to do during VATS. Fourteen (8.4%) of these pa-
tients had malignant nodules. Both of these results surprised
us. However, an incidence of 20% to 40% of nonimaged
nodules discovered at the time of bimanual lung palpation
is consistent with the literature for patients who undergo tho-
racotomy and metastasectomy. We4 reported in 1994 that
29.2% of patients who had renal cell carcinoma had nodules
that were missed by the preoperative chest CT scan but were
discovered by bimanual palpation at the time of thoracotomy.
Rena and associates8 reported in 2007 an 11% incidence of264 The Journal of Thoracic and Cardiovascular Surgery c Febnonimaged pulmonary metastasectomy for breast cancer.
Parsons and associates5 in 2004 reported an incidence of
22% for metastasectomy. Thus, the literature demonstrates
a significant number of nonimaged pulmonary nodules that
are only discovered when the lung is carefully palpitated in
between two hands at the time of open thoracotomy, despite
the use of 5-mm cut CT scan. However, this information is
only on those who undergo metastasectomy. The clinical im-
pact of nonimaged pulmonary nodules for metastasectomy is
real. The most significant predictor of survival in patients
with soft tissue osteogenic sarcoma, melanoma, and renal
cell carcinoma has been shown to be the ability to render
the patient disease free.14 However, we do not know whether
this concept also applies with patients who have NSCLCs
that are not resected. Furthermore, we were surprised withruary 2008
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TSTABLE 3. Distribution of the missed pulmonary nodule based on the known preoperatively imagined nodule's location
Location
of known
preoperatively
imaged primary
No. of
patients
in study with
primary tumors in this
lobar location
Location of missed nodule
RUL RML RLL LUL LLL
RUL 69 (42%) -


-

RML 9 (5%)
RLL 16 (10%) -

--

LUL 45 (27%) ----

LLL 27 (16%)


RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.-5M1; 5 another primary; 5 benign nodule.this high incidence because we expected it to be lower in this
series compared with the incidence in previous reports be-
cause of the improvement in imaging technology. We also
anticipated a lower incidence for several other reasons: the
study was prospective, the CT used 5-mm cuts with intrave-
nous contrast, the scans were read by chest radiologists, the
vast majority of patients had their scan performed at our
institution, which is a specialized tertiary center with four ra-
diologists who specialize in chest radiology, and all outside
films were interpreted at UAB. In addition, we also review
all scans before resection. Finally patients received an inte-
grated PET/CT scan. However, the scanner for integrated
PET/CT in our and most institutions only offers 16- instead
of 64-slice technology and nodules 6 to 8 mm or smaller
are not PET-visible. Finally, we believed that because this
study was performed on patients with NSCLC and not hem-
atogenously disseminated metastases, the incidence of other
malignant pulmonary nodules would be lower.
Because of these findings, we retrospectively re-reviewed
all of the CT scans in these 37 patients to evaluate whether the
‘‘nonimaged but bimanually palpable’’ pulmonary nodule re-
ally was ‘‘imaged’’ but just not described on the chest CT
scan report and was also missed by our inspection of the chest
CT scan before the operation. We used our intraoperative
findings to help guide our retrospective review. We also
looked for a ‘‘reason’’ why the nodules may have been
missed (eg, atelectasis). Using this technique, we found
that in 17 (46%) of the 37 patients and in 6 (43%) of the 14
with malignant nodules, the nodules in retrospect may haveThe Journal of Thorbeen imaged. It is not uncommon for patients to have small
2 to 6 mm–sized nodules that are not described by the radiol-
ogist or by our review on the scan report. We also found other
additional nodules as well that may have been missed but
were not palpated.
In this study, we generously assumed that if a patient were
to undergo a VATS lobectomy, all the mediastinal N2 lymph
nodes would be completely removed as we do during an open
thoracotomy and lobectomy. This assumption is of course not
true for all surgeons who perform VATS lobectomy, nor is it
true for all or most surgeons who perform open lobectomy as
well.15 We found that 12 patients also had unsuspected N2
disease, and this again argues for mediastinal lymph node re-
moval or at least biopsy of all assessable N2 stations at the
time of resection to prevent stage migration irrespective of
whether the surgical approach is VATS or open.
We found that 14 nonimaged (or perhaps we should more
accurately describe them as nondescribed) pulmonary nod-
ules were malignant and 23 were benign. Of concern is the
fact that the majority of the patients who had malignant un-
suspected pulmonary nodules had a T1 lesion (64%). One
might expect the patients with the larger T2 tumors to have
been more likely to have had an unimaged M1 nodule in an-
other lobe, but that was not our finding. As expected, those
patients with squamous cell were more likely to have a non-
imaged malignant nodule than those with adenocarcinoma. If
one considers the maxSUV of the known imaged NSCLC, it
was predictive. The median maxSUV of the known cancer in
the 14 patients with nonimaged malignant nodules was 5.0acic and Cardiovascular Surgery c Volume 135, Number 2 265
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TScompared with 4.1 for the 152 who did not have a nonimaged
malignant nodule (P 5 .045).
An initially suggested design for this study was to start off
all procedures with a VATS and then perform finger palpa-
tion over the surface of the lung and have the findings re-
corded. Then a thoracotomy could have been performed
and bimanual palpation carried out. This design was not cho-
sen because of institutional review board concern that this de-
sign may have altered the standard of care that we currently
use for those patients with NSCLC, which is thoracotomy
without the added operative time and cost of first performing
a VATS. However, despite the design chosen, it is highly un-
likely that any of these relatively deep 6 mm or smaller nod-
ules would have been palpable via VATS since all nodules
were only discovered by careful bimanual palpation.
Interestingly, of the 14 patients with malignant nodules, 9
had M1 lesions and 5 had small second primary tumors. By
definition, the 9 patients’ nodules that are labeled M1 lesions
could represent second primary tumors of the same histologic
classification and have a more favorable prognosis. We
treated the 5 patients’ nodules that had different histologic
characteristics only with a segment. No patients in this series
received a pneumonectomy for the unsuspected nonimaged
findings. Thus the question should also be raised whether
we adequately treated these unsuspected nodules that were
not M1 lesions but were new T1 lesions? If not, does the po-
tential increased morbidity of performing an open procedure
outweigh the potential benefits of better intraoperative stag-
ing if unsuspected findings are not adequately treated? More-
over, does the added morbidity or performing a wedge
resection in the lobe that is not removed for a nodule that
turns out to be benign nodule add morbidity as well? The an-
swers to these questions remain unknown. Recently, we have
conducted four randomized prospective studies (three pub-
lished)16 to find ways to reduce the pain of open thoracotomy.
We believe that the difference between open thoracotomy
and lobectomy compared with VATS lobectomy has been
significantly reduced with some of these techniques. The
pain of thoracotomy has been drastically reduced by three
measures: by avoiding the lower intercostal nerve by drilling
holes in the inferior rib and using intracostal sutures instead
of pericostal sutures,17 by harvesting an intercostal muscle
flap before chest retraction to avoid retractor injury to the in-
tercostal nerve of the space over which the chest is entered,18
and by injecting a local anesthetic for pre-emptive analgesia
in several intercostal nerves before chest retraction19 Our pa-
tients are encouraged to return to full activity 3 weeks after
thoracotomy.
Finally, the clinical impact of this study’s findings is
unknown. VATS lobectomy is performed well by many
surgeons, and the long-term survival of several VATS
lobectomy series for NSCLC is comparable with those of
open series. Walker in 200320 reported a 5-year survival of
77.9% for patients with stage I NSCLC who underwent266 The Journal of Thoracic and Cardiovascular Surgery c FebVATS. Similarly, Roviaro and associates21 in 2004 reported
a 5-year survival in patients with T1 N0 NSCLC of 70% and
a survival of 56% in patients with T2 N0 NSCLC. Recently,
Shigemura and coworkers22 from Japan reported an incredi-
ble 96.7% 5-year survival for patients with clinically staged
IA NSCLC. McKenna and colleagues,23 the true pioneers
of VATS lobectomy, reported in 1998 a Kaplan–Meier 4-
year survival for stage I NSCLC of 70%. If one argues that
these palpated lesions are not clinically significant and that
they will be identified later in the patient’s follow-up studies
and will be resected, then the cost of the second operation, the
restaging tests, and the risk assessment studies needed before
that reoperation occur all need to be considered. In addition,
the added stress to the patient should be considered.
In conclusion, this prospective study finds that open lo-
bectomy that affords bimanual palpation of the rest of the
lung and not just digital palpation over the surface of the
lung may discover nonimaged malignant pulmonary nodules
in different lobes other than the one to be resected in 8.4% of
patients with NSCLC. This finding is true despite the use of
preoperative fine-cut 64-slice chest CT scan with 5-mm slices
and intravenous contrast and integrated FDG-PET/CT scan.
However, the clinical impact of these findings and of these
small malignant pulmonary nodules is unknown.
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Discussion
DrThomasA. D’Amico (Durham, NC). I congratulate both authors
for this thoughtful study that describes the incidence of nodules that
may have been missed at resection for lung cancer, a concept derived
from experience with thoracoscopic metastasectomy.
Just as with metastasectomy, it is possible that thoracoscopic ex-
ploration for resection of lung cancer will miss nodules, some of
which may be malignant. However, in this study, as in others, the
majority of missed nodules are benign. Regarding the malignant
nodules, the presence has been demonstrated, but the significance,
as you said, has not. I and others, I’m sure, are surprised that so
many of the nodules missed were 6 mm or larger, including all 3
of the noncarcinoid second primary lesions. One would expect
a 64-slice scanner to perform better.
Future studies are required to elucidate the significance of these
missed nodules in patients with both benign and secondary pulmo-
nary malignancy. It is possible that sequential thoracoscopic proce-
dures have a better outcome than thoracotomy in some patients,
depending on the biology of the tumor.
In light of your study and these comments, I have four questions.
What percentage of your patients underwent mediastinoscopy? You
found many more patients with N2 disease than with second primary
lesions.
Second, why did you not include thoracoscopic exploration as
part of your study to determine the true incidence of the missed nod-The Journal of Thoules? Thoracoscopic exploration may have found pleural or other
disease that would preclude thoracotomy.
Third, in this study, 14 of 166 patients had missed malignant
nodules. Of these 14, 9 of 14, or 5%, were thought to have M1 le-
sions. Five of those 9 already met criteria for adjuvant chemother-
apy. Thus only 4 patients, or 2%, had nodules that were found
that changed their therapy.
As well, 5 of 166 patients were thought to have second primary
tumors. Two of these 5 tumors were carcinoids, and although you
refute that they are tumorlets, by definition they are. Tumorlets are
carcinoids 5 mm or less that do not show up on CT scan, so by def-
inition these are tumorlets. One of the 5 was a pleura-based nodule
that you would have thought could have been found thoracoscopi-
cally. One of the 5 that you resected was actually N2. Therefore,
there is only 1 patient left with a second primary that definitely
can be said to have benefited, and it is not certain that a second
thoracoscopic procedure would have been less effective than that.
Finally, you found many more benign lesions than malignant
ones. Do you completely discount the potential negative effects of
these added resections?
I appreciate the authors for investigating these difficult issues.
Dr Cerfolio. Dr D’Amico, thank you very much. Four questions
but actually six sentences that require my comment. First of all, all
nodules were 6 mm or less, not 6 mm or greater. All nodules were 6
mm or less.
Second, you said that more patients had N2 disease. That is not
true. Twelve patients had N2. That’s 7%. That’s less than 14 patients
who had malignant disease.
Dr D’Amico. According to the manuscript, the majority were
6 mm or larger.
Dr Cerfolio. No, they were not. You can go back and look at
Table 2.
Dr D’Amico. I have your manuscript.
Dr Cerfolio. No, I’m talking about the nodules that we found at
the time of surgery. They were all 6 mm or less.
Dr D’Amico. As to the second issue, I said there were more with
N2 disease than second primary lesions. We would all argue that it is
important prognostically to find M1 disease, and no one would ar-
gue that it is not, but we are probably not going to affect the survival
of those patients, and, in fact, the original thoracotomy was a nega-
tive effect. However, more N2 disease was found than second
primary disease.
Dr Cerfolio. There were more N2 lesions found than second pri-
mary lesions, that’s true, but I do not know the clinical significance
of that. However, there were more patients who had malignant pul-
monary nodules than had unsuspected N2. You asked me when we
do mediastinoscopy. Well, as you know, any time a CT scan ques-
tions an N2 or an integrated PET/CT scan questions an N2, we do
mediastinoscopies. In this series, I think 38 or 40 patients got media-
stinoscopy. If any of them were positive, they were eliminated from
this study. All these were mediastinoscopy-negative. Actually, 1 of
them had a positive 4R, so it was a falsely negative mediastinoscopic
result. All the rest of them were in endoscopic ultrasound range. We
did not routinely use endoscopic ultrasound because of the prospec-
tive study we published in Chest in December 2006 (130:1791-5).
Your next question was about, by definition, what is a tumorlet.
By definition, a carcinoid tumorlet is a carcinoid not seen by CT
scan, less than 5 mm. Go back and look at the size in the table of
the carcinoids that were removed.racic and Cardiovascular Surgery c Volume 135, Number 2 267
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TSFinally, you asked about the morbidity of removing benign nod-
ules. That is a very good question. I do think that because you are
using a Bovie electrocautery device (Bovie Medical Corporation,
St Petersburg, Fla), you are using a stapler, you are getting inflam-
mation in the part of the lung that you want to leave, and I do think
that there is morbidity in that. I think it is a very good point.
Dr D’Amico, we are on the same page. I think your comments
are great.
Dr Raja M. Flores (New York, NY). I think this is a very inter-
esting paper, but I would be very cautious about how you incorpo-
rate these data into your clinical practice. The implications are that
you should not be doing a VATS lobectomy because you would
miss lesions that you would otherwise find at thoracotomy. Then
you need to take it one step further: Do we do a sternotomy or bilat-
eral thoracotomy to palpate the contralateral lung? I think these data,
while interesting, need to be looked at a little more in depth.
Dr Cerfolio. That is the same comment that we hear all the time
about metastasectomies. If you believe that you are going to find
more nodules at the time of thoracotomy, why not explore both
sides? I would caution you and say that those data are looking at
the nodules in the same lung. We have no data that the incidence
is as high in the other lung, especially if the scan shows no nodules
there. So be careful not to assume that just because we find more nod-
ules when the CT scan shows 1 or more, we will find 1 nodule when
the CT shows none. I do not know of any data that would suggest to
just randomly explore a chest that has no evidence of a nodule.268 The Journal of Thoracic and Cardiovascular Surgery c FebDr Nasser K. Altorki (New York, NY). You may have men-
tioned it already, but was there a correlation between the size of
the index lesion and the presence of these secondary nodules?
Dr Cerfolio. I tried to show that in one pie graph. I figured most
of these patients would have T2, larger lesions. They did not. Most
were T1. So 9 of these patients had T1 lesions, less than 3 cm, and
yet they had unsuspected malignant nodules.
Dr. Altorki. This is a pretty broad category. A 3-cm tumor and
a 1-cm tumor are clearly different.
Dr Cerfolio. You are right. I would have to go back and see the
exact size.
Dr Steven D. Herman (Brooklyn, NY). What do you think the
impact on the study outcome and conclusions would be of doing
the CT scans at 1-mm cut slices as opposed to 5-mm cuts, providing
higher resolutions of small lesions, or by repeating studies closer to
the surgery date if the studies are aged? Given the fast speed of CT
scanning available in 64-slice machines, this may offer more accu-
rate imaging.
Dr Cerfolio. Without studying it, I do not know the answer, but
my guess is that we would find more of these nodules. As Dr
D’Amico said, we are going to find a lot more benign nodules as
well. Then we are going to go to the operating room and do a right
thoracotomy. I will say in the operative note that there’s a 2-mm
nodule in the left upper lobe or 1-mm nodule in the left lower
lobe that I am assuming is benign, but I proceeded with resection.
I think we are going to see more of these.ruary 2008
